Bayer inks $290M collaboration deal with Ortho-McNeil

Bayer Healthcare has struck a $290 million deal to develop a new drug for blood clots with Johnson & Johnson. Bay 59-7939 is set to begin late-stage trials in the next few weeks. J&J's Ortho-McNeil will make an upfront payment and share in the global development costs of the drug.

- read this AP article for more